Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monosialic Gangliosides to Prevent Paclitaxel Neurotoxicity
NCT04222790Phase 2Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2020
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of monosialotetrahexosylganglioside in taxane-induced peripheral neuropathy (TIPN), sponsored by Henan Cancer Hospital. Started Aug 2020; status: completed.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
taxane-induced peripheral neuropathy (TIPN)
Beyond the preview
Go deeper on NCT04222790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04222790.